Unmet Needs in Advanced or Metastatic TRK Fusion+ Thyroid Cancer
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.
According to Cabanillas, more options for RET, ALK, and BRAF mutations exist. TRK mutations are another rare fusion requiring a TRK inhibitor. Additionally, there are limitations on the 2 currently approved therapies sorafenib (Nexavar) and lenvatinib (Lenvima). For some patients, these therapies are too toxic, according to Cabanillas.
For patients who have a predisposition for bleeding, especially bleeding from the tumor VEGF inhibitors may be too unsafe as the increase bleeding risk. There is a need for more tolerable therapies for this patient population.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
